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Abstract: TP53 is one of the most frequently-mutated and deleted tumor suppressors in cancer, with
a dramatic correlation with dismal prognoses. In addition to genetic inactivation, the p53 protein can
be functionally inactivated in cancer, through post-transductional modifications, changes in cellular
compartmentalization, and interactions with other proteins. Here, we review the mechanisms of p53
functional inactivation, with a particular emphasis on the interaction between p53 and IκB-α, the
NFKBIA gene product.
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1. Introduction
TP53 is the most renowned tumor suppressor among clinicians and researchers, and is one of
the most extensively studied [1–4]. Its fame arises from the impressive frequency of TP53 genetic
inactivation in about 50% of cancers [5,6], the dismal association with prognoses [7,8], and the ability
to regulate cellular fate [9] (Figure 1). While the role of p53 in cancer has mostly been associated
with the genetic inactivation of TP53 through mutations and deletions [1,10], various novel p53
functions and targets have been discovered, with impressive consequences in tumorigenesis [1,11,12]
and cancer therapy [13–16]. Indeed, the role of p53 in cancer should include the following,
novel, non-canonical functions: (i) various TP53 mutations behave as gain of functions [1,17–20];
(ii) the p53 protein is no longer just a transcriptional factor [21–24], but acts in different cellular
compartments outside the nucleus, where it mediates several processes through a complex network
of partners [25–28]; (iii) wild-type p53 should also result in being functionally inactive through
changes in compartmentalization or protein modifications [29–31]; and (iv) non-cell-autonomous
tumor suppression properties of p53 have also been discovered [32]. All together, these intriguing p53
functions suggest that the role of p53 in cancer is much more complex and may be exploited from a
therapeutic standpoint [15,33,34]. It is, indeed, clear that the restoration of p53 in various cancer models
is responsible for cancer eradication [35,36], however, unfortunately, no strategies are, in general,
available to restore p53 when it has been genetically deleted or mutated [37]. However, targeting the
mechanisms that are responsible for p53 inactivation by changes in compartmentalization or aberrant
functions may promote p53 reactivation with dramatic consequences for the cancer itself, such as
induction of apoptosis, or they may allow restoration of sensitivity to chemotherapy [38–40]. In this
review, we will focus on mechanisms that are responsible for p53 functional inactivation by changes
in compartmentalization or by protein interactions, and on strategies to reactivate p53. In particular,
we will describe the role of IκB-α as a potentially relevant p53 partner.
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Figure 1. p53 pathway. A simplified representation of the apoptotic signaling pathway and p53 
negative regulation by E3 ubiquitin-protein ligase Mdm2. Under stress conditions, enhanced p53 
activity promotes transcription of downstream targets, such as p21, which trigger cell cycle arrest or 
induce cellular apoptosis. Ub: ubiquitin; PUMA: p53 upregulated modulator of apoptosis; BAX: 
Bcl-2-associated X protein; NOXA: phorbol-12-myristate-13-acetate-induced protein 1 (also known as 
PMAIP1). Activation or “transition-states” such as phosphorilation or ubiquitination, are shown in 
arrowhead; Inhibition is represented as an arrow with transversal bar. 
2. p53 Functional Inactivation 
2.1. Mechanisms of p53 Shuttling 
Aberrant tumor suppressor compartmentalization is a known mechanism of functional 
inactivation for various tumor suppressors [41,42]. Tumor suppressors may shuttle, as a 
consequence of point mutations (such as NPM1 in acute myeloid leukemia [43]) or aberrant 
regulations [42]. Notably, the mechanisms of nucleo-cytoplasmic transport offer challenging 
opportunities as a therapeutic target in various cancers [44]. This last mechanisms is, indeed, the 
most frequent cause of protein shuttling, as described for FoxO [45,46], PTEN [47], p27 [48], and 
many others [41]. The p53 protein is also a nuclear-cytoplam shuttling protein, due to the presence of 
two nuclear export signals (NES), one located within the C-terminal oligomerization domain and 
one in the N terminus, as well as a nuclear localization signal (NLS) at its C-terminal domain [49,50]. 
p53 shuttling is also modulated by mono-ubiquitination, while poly-ubiquitination is responsible of 
p53 degradation. Mono-ubiquitination of p53 promotes its translocation from the nucleus to the 
cytoplasm [51–54]. Notably, while Mdm2 is the E3 ligase promoting p53 poly-ubiquitination, the 
contribution of Mdm-2 in mediating p53 mono-ubiquitination is much more complex [55]. In 
particular, it was demonstrated that low levels of Mdm2 activity dictate p53 mono-ubiquitination, 
while high levels promote polyubiquitination [53]. To increase the complexity of the mechanisms of 
regulation of p53 delocalization by ubiquitination, it should be noted that other enzymes are 
involved in p53 monoubiquitination. In particular, the E3 ligase, Msl2, was shown to mediate p53 
Figure 1. p53 pathway. A simplified representation of the apoptotic signaling pathway and p53
negative regulation by E3 ubiquitin-protein ligase Mdm2. Under stress conditions, enhanced p53
activity promotes transcription of downstream targets, such as p21, which trigger cell cycle arrest
or induce cellular apoptosis. Ub: ubiquitin; PUMA: p53 upregulated modulator of apoptosis; BAX:
Bcl-2-associated X protein; NOXA: phorbol-12-myristate-13-acetate-induced protein 1 (also known as
PMAIP1). Activation or “transition-states” such as phosphorilation or ubiquitination, are shown in
arrowhead; Inhibition is represented as an arrow with transversal bar.
2. p53 Functional Inactivation
2.1. echanis s of p53 Shuttling
berrant tu or suppressor co part entalization is a kno n echanis of functional
inactivation for various tumor suppressors [41,42]. Tumor suppressors may shuttle, as a consequence
of point mutations (such as NPM1 in acute myeloid leukemia [43]) or aberrant regulations [42].
Notably, the mechanisms of nucleo-cytoplasmic transport offer challenging opportunities as a
therapeutic target in various cancers [44]. This last mechanisms is, indeed, the most frequent cause of
protein shuttling, as described for FoxO [45,46], PTEN [47], p27 [48], and many others [41]. The p53
protein is also a nuclear-cytoplam shuttling protein, due to the presence of two nuclear export signals
(NES), one located within the C-terminal oligomerization domain and one in the N ter inus, as
well as a nuclear localization signal (NLS) at its C-terminal domain [49,50]. p53 shuttling is also
modulated by mono-ubiquitination, while poly-ubiquitination is responsible of p53 degradation.
Mono-ubiquitination of p53 promotes its translocation from the nucleus to the cytoplasm [51–54].
Notably, while Mdm2 is the E3 ligase promoting p53 poly-ubiquitination, the contribution of
Mdm-2 in mediating p53 mono-ubiquitination is much more complex [55]. In particular, it was
demonstrated that low levels of Mdm2 activity dictate p53 mono-ubiquitination, while high levels
promote polyubiquitination [53]. To increase the complexity of the mechanisms of regulation of
p53 delocalization by ubiquitination, it should be noted that other enzymes are involved in p53
monoubiquitination. In particular, the E3 ligase, Msl2, was shown to mediate p53 monoubiquitination,
and subsequent shuttling into the cytoplasms, in a Mdm2-independent manner [56]. Notably,
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Msl2 is not involved in the degradation of p53. Similarly, the NEDD4-like WWP1 E3 ligase was shown
to promote p53 nuclear export, in a Mdm2 dispensable manner [57]. p53 ubiquitination is counteracted
by the de-ubiquitinase HAUSP, rendering the mechanisms of p53 mono/poly-ubiquitination highly
complex [58]. Furthermore, the result of shuttling versus degradation of p53 is a consequence
of a dynamic process encompassing many cellular components and, at least at the moment, the
development of strategies to modulate p53 localization with specific inhibitors is debatable, but
attractive. However, it is clear that the mechanisms that promote p53 nuclear exclusion may also
be able to promote the loss of the nuclear tumor suppressive function of p53, with clear implication
in tumorigenesis.
2.2. p53 Regulatory Proteins
An additional mechanism for p53 functional inactivation is exerted by the activity of various
p53-interacting proteins that are able to (i) prevent p53 to function as a transcriptional factor;
and (ii) favor aberrant p53 cellular compartmentalization and activity [59].‘Among the several
p53-interacting proteins, it is worth mentioning the functions of few of them. The Mdmx protein is
an essential component of the p53 regulatory machinery, which includes Mdm2 [60]. While Mdm2
acts as an E3 ligase, which promotes p53 degradation, the Mdmx protein physically interacts with
the transcriptional domain of p53, preventing it from mediating gene expression. Mdmx/p53 is
an example of how genetically wild-type p53 can be functionally inactivated by interaction with a
partner. Similarly, the Tax protein was shown to interfere with the transactivation function of p53 in
adult T cell leukemia, and, in particular, in HTLV-I transformed cells [61,62]. Other partners, such as
E2F [63], NPM [64], and many others, reviewed elsewhere [59], play an essential role in regulating p53
functionality. However, due to the complexity of such regulations, it is difficult to precisely determine
the role of these interactions in cancer pathogenesis.
It should also be noted that TP53 mutations may affect the landscape of p53-interacting proteins,
with consequent aberrant and novel gains or losses in functions [1,18,65–67]. In particular, p53 mutants
can interact with a different set of proteins, such as Tap63, compared to wild-type p53 [68,69], or may
also affect downstream targets in a complete different manner when compared to normal p53, as was
recently observed with p21WAF1 [70]. The landscape of wild-type and mutant p53 partners is indeed
expanding dramatically [25], rendering the study of the biological relevance of all these new networks
highly complex, but also offering new opportunities to target cancers with mutant p53.
3. The IκB-α/p53 Connection
p53 activity is known to be intimately connected with NF-κB signaling [71,72]. In particular,
NF-κB/p53 crosstalk has been associated with various phases of tumorigenesis, including
transformation, metastatization, and immunological surveillance. It was demonstrated that NF-κB
may either antagonize or cooperate with p53 [73]. Among the different mechanisms, the NF-κB/p53
connection appeared to be dependent on IKK kinase [73,74], which is also involved in the
phosphorylation and subsequent degradation of IκB-α.
Notably, IκB-α, the product of the NFKBIA gene, was also described as a p53-interacting protein
able to modulate p53 functions. IκB-α is mostly renowned as the inhibitor of NF-κB, due to its
ability to bind to the p65/p50 dimers, preventing them from translocating into the nucleus, therefore,
counteracting NF-κB signaling [75,76]. Upon stimulation, IκB-α is degraded by the proteasome,
enabling NF-κB to shuttle into the nucleus where it acts as a transcriptional factor. IκB-α is also
known in the clinical environment because the proteasome inhibitor bortezomib, routinely used to
treat multiple myeloma, is able to prevent IκB-α degradation, therefore blocking NF-κB signaling [77].
A few manuscripts have been published that demonstrate that IκB-α is, not only able to modulate
NF-κB signaling, but is also able to promote p53 functional inactivation [78–81]. In an original report, it
was shown that IκB-α/p53 is formed, both in the cytoplasm, and in the nucleus under basal conditions,
and is dissociated in response to apoptotic stress, DNA damage, hypoxia, and TGF-β stimulation [78].
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A yeast two-hybrid system allowed mapping of the interaction sites involved in the binding of p53.
In particular, the non-ankyrin C terminus of IκB-α interacts with the proline-rich region of p53, while
the phosphorylation of p53 at ser46 is involved in the regulation of the interaction. This interaction was
also confirmed by another group that demonstrated that the protein structure of p53 is similar to that
of the p65 subunit of NF-κB [80]. Following this evidence, the authors claimed, and demonstrated, that
IκB-α is able to bind to both p65 and p53, and, in both cases, this interaction inactivates the partners.
These two works, however, lead to two partially different conclusions. One demonstrated that the
interaction of IκB/p53 suppresses p53 activity, while, in the other, the exogenous co-expression of both
proteins was associated with increased apoptosis induction. This discrepancy may be explained by the
experimental approaches, since exogenous expression of proteins might not reproduce physiological
processes. A third work was subsequently published, clearly demonstrating that, when IκB-α is
mutated on the two serine residues that dictate its degradation, IκB-α is stable in the cytoplasm and is
bound to both p53 and p65 [81]. As a consequence, the transcriptional activities of both p65 and p53
are suppressed. This observation was also consistent with the fact that expression of this mutant form
of IκB-α was shown to suppress p53-dependent apoptosis in lymphoblastic leukemia, as demonstrated
by another group [79]. The removal of the ankyrin repeated domain and the NES domain in IκB-α
promotes the location of IκB-α into the nucleus, where it was shown to promote both p65 and p53
transcriptional activities. Again, while the use of mutants may affect the physiological function of the
IκB-α/p53 interaction, this work further supports the notion that IκB-α/p53 is a potentially-relevant,
novel network that is involved in the functional inactivation of p53. It should also be noted that
NF-κB is able to directly regulate p53 and vice versa, and, therefore, the net result of p53 regulation
by IκB-α mutants may not necessary recapitulate the direct interaction with p53. In addition to the
experimental evidence that supports the IκB-α/p53 complex, it is also needed to investigate whether
this network is important in cancer specimens. Recently, we observed that, in chronic myeloid leukemia
(CML), a myeloproliferative disorder sustained by the t(9:22) translocation coding for the chimeric
protein BCR-ABL [82,83], the IκB-α protein is highly expressed in the cytoplasm [84]. Notably, we also
documented that cytoplasmic IκB-α is bound to p53 in primary CML cells (Figure 2). Interestingly,
this interaction does not appear to be mediated by tyrosine phosphorylation of IκB-α by BCR-ABL, as
IκB-α was not found to be tyrosine-phosphorylated by BCR-ABL in primary cells and in in vitro kinase
assays. Therefore, we speculated that BCR-ABL simply physically interacts with IκB-α, and that this
event may favor some conformation changes or other modifications in IκB-α, which, in turn, promotes
interaction with p53. As a consequence, p53 is excluded from the nucleus and loses its nuclear tumor
suppressive role. We have observed that p21, a p53 target, is significantly down-modulated in CML and
is restored to normal levels upon treatment with imatinib, the BCR-ABL inhibitor [84]. Interestingly,
very recent work has demonstrated that p53 targets are downregulated in CML. While this observation
may be coherent with our data [85], in this manuscript, p53 did not appear to be excluded from the
nucleus. It could be possible that p53 nuclear exclusion, as observed for PTEN compartmentalization
in CML [47], is dependent on the differentiation status of the cells. In the case of PTEN, for instance,
only progenitor cells are characterized by PTEN nuclear exclusion, while CML stem cells retain
physiologically diffuse localization [47]. It is possible, and should be experimentally investigated,
that p53 cellular compartmentalization is different in CML progenitors versus primitive CML CD34+
CD38− stem cells. Notably, this process appears to be therapeutically relevant because treatment with
imatinib promoted p53 such that it shuttled back into the nucleus [84]. Further analyses should be
performed to assess whether p53 is trapped in the cytoplasm by IκB-α in challenging Philadelphia
positive scenarios, such Ph+-ALL or Tyrosine Kinase Inhibitor (TKI)-resistant CML. In these contexts,
restoring p53 into the nucleus may have profound consequences and may favor leukemia eradication.
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Figure 2. IκB-α/p53 network in chronic myeloid leukemia (CML). IκB-α/p53 network is summarized 
in the context of CML. In BCR-ABL leukemia cells, IκB-α interacts with BCR-ABL and with p53. The 
BCR-ABL/IκB-α complex prevents p53 translocation into the nucleus and inhibits its tumor 
suppressive functions. Activation or “transition-states” such as phosphorilation or ubiquitination, 
are shown in arrowhead; Inhibition is represented as an arrow with transversal bar. 
4. Targeting the IκB-α/p53 Network 
Various works have clearly demonstrated that IκB-α and p53 are part of a novel network [78–
81,84]. Targeting upstream proteins, such as BCR-ABL, favors the restoration of p53 into the nucleus, 
as we noted. Thus, strategies that aim at disrupting the IκB-α/p53 network would favor p53 nuclear 
pool restoration, specifically in contexts where BCR-ABL inhibition is no longer sufficient to 
promote cancer apoptosis induction. Currently, no strategies to disrupt IκB-α/p53 interaction have 
been described and, therefore, here, we simply speculate on the effects of the clinically-available IKK 
inhibitors and proteasome inhibitors on this complex. IKK inhibitors block the phosphorylation of 
IκB-α, which is indeed unable to be degraded, since phosphorylation primes IκB-α to ubiquitination, 
while proteasome inhibitors indirectly stabilize IκB-α, blocking proteasome activity. In the absence 
of data, it is debatable to speculate on the consequences of these drugs on the IκB-α/p53 complex 
because, as is well documented, these drugs significantly impact NF-κB function, and the final 
biological consequences may be a balancing of effects toward p53 and NF-κB. However, IKK 
inhibitors and IκB-α inhibitors may substantially increase the levels of IκB-α protein, and may favor 
the generation of the IκB-α/p53 complex. It is possible that acquired resistance to these drugs, or the 
refractoriness observed in some patients, is the consequence of the trapping of p53 in the cytoplasm, 
which thwarts NF-κB inhibition. Consequently, a potential therapeutic strategy should be a drug 
that stabilizes IκB-α, with consequent NF-κB inhibition, and which prevents binding with p53, 
therefore inducing apoptosis. 
5. Discussion 
The functional inactivation of tumor suppressors, and in particular p53, is an essential novel 
concept that may offer promising therapeutic opportunities [34,44]. On the one hand, p53 
inactivation either through mutations or aberrant regulations may bring out novel targets, as was 
recently pointed out with the DNA damage pathway and Arf regulation [86]. On the other hand, p53 
inactivation allows for the design of novel therapies that are able to promote its re-activation, with 
Figure 2. IκB-α/p53 network in chronic myeloid leukemia (CML). IκB-α/p53 network is summarized
in the context of CML. In BCR-ABL leukemia cells, IκB-α interacts with BCR-ABL and with p53.
The BCR-ABL/IκB-α complex prevents p53 translocation into the nucleus and inhibits its tumor
suppressive functions. Activation or “transition-states” such as phosphorilation or ubiquitination, are
shown in arrowhead; Inhibition is represented as an arrow with transversal bar.
4. Targeting the IκB-α/p53 Network
Various works have clearly demonstrated that IκB-α and p53 are part of a novel network [78–81,84].
Targeting upstream proteins, such as BCR-ABL, favors the restoration of p53 into the nucleus, as we
noted. Thus, strategies that aim at disrupting the IκB-α/p53 network would favor p53 nuclear pool
restoration, specifically in contexts where BCR-ABL inhibition is no longer sufficient to promote cancer
apoptosis induction. Currently, no strategies to disrupt IκB-α/p53 interaction have been described
and, therefore, here, we simply speculate on the effects of the clinically-available IKK inhibitors
and proteasome inhibitors on this complex. IKK inhibitors block the phosphorylation of IκB-α,
which is indeed unable to be degraded, since phosphorylation primes IκB-α to ubiquitination, while
proteasome inhibitors indirectly stabilize IκB-α, blocking proteasome activity. In the absence of data,
it is debatable to speculate on the consequences of these drugs on the IκB-α/p53 complex because,
as is well documented, these drugs significantly impact NF-κB function, and the final biological
consequences may be a balancing of effects toward p53 and NF-κB. However, IKK inhibitors and IκB-α
inhibitors may substantially increase the levels of IκB-α protein, and may favor the generation of the
IκB-α/p53 complex. It is possible that acquired resistance to these drugs, or the refractoriness observed
in some patients, is the consequence of the trapping of p53 in the cytoplasm, which thwarts NF-κB
inhibition. Consequently, a potential therapeutic strategy should be a drug that stabilizes IκB-α, with
consequent NF-κB inhibition, and which prevents binding with p53, therefore inducing apoptosis.
5. Discussion
The functional inactivation of tumor suppressors, and in particular p53, is an essential novel
concept that may offer promising therapeutic opportunities [34,44]. On the one hand, p53 inactivation
either through mutations or aberrant regulations may bring out novel targets, as was recently pointed
out with the DNA damage pathway and Arf regulation [86]. On the other hand, p53 inactivation allows
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for the design of novel therapies that are able to promote its re-activation, with the important induction
of cancer selective apoptosis. Various tumor suppressors have been shown to be functionally inactive
in cancer, such as p27, FoxO, PTEN, and p53. In this work, we have described a few mechanisms that
are able to inactivate p53, which include protein shuttling and protein inactivation by p53-interacting
partners. Among these partners, we have discussed, in detail, the role of IκB-α, as an essential mediator
of either the p53 or p65 subunit of NF-κB. While the interaction has already been demonstrated
in various models and contexts, the potential therapeutic relevance is still waiting for a deeper
investigation, but may represent a new opportunity to restore p53 functions.
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